

# GSK delivers strong 2025 performance and reaffirms long-term outlooks

"GSK delivered another strong performance in 2025, driven mainly by Specialty Medicines, with double-digit sales growth in Respiratory, Immunology & Inflammation (RI&I), Oncology and HIV. Good R&D progress also continued, with 5 major product approvals achieved and several acquisitions and new partnerships completed to strengthen the pipeline further in oncology and RI&I. We expect this positive momentum to continue in 2026, which will be a key year of execution and operational delivery with strong focus on commercial launches and accelerating R&D. We are well placed to move forward in this next phase for GSK - to deliver our outlooks - and to create new value for patients and shareholders."

**Luke Miels**  
Chief Executive Officer, GSK



**Specialty Medicines**  
**£13.5bn** +17%  
Respiratory, Immunology and Inflammation +18%  
Oncology +43%  
HIV +11%

**Vaccines**  
**£9.2bn** +2%

**General Medicines**  
**£10.0bn** -1%

Core operating profit	Total EPS	Core EPS	Dividend Q4	FY
£9.8bn +11%	141.1p >100%	172.0p +12%	18p	66p

2025	Expected in 2026
5 major FDA approvals	2 new major product approvals

7 pivotal trial starts

5 pivotal readouts

10 pivotal trial starts

2026 guidance	Core operating profit growth
Turnover growth 3-5%	7-9%

**2031 sales outlook**  
**>£40bn**

Journalists/media see press release on [www.gsk.com](http://www.gsk.com) for full details on full-year and Q4 2025. Please read the cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures on pages 20-21 and 53-56 of the press release. Product group sales may not add to total sales due to rounding. References to growth are at constant exchange rates (CER) unless stated otherwise.